NeuroMetrix, Inc. (NASDAQ:NURO) is reporting third quarter earnings results on Thursday 22nd October 2020, before market open.
Previous Quarter Performance
NeuroMetrix, Inc. announced loss for the second quarter of $ 0.25 per share, from the revenue of $ 1.36 million.
Stock Performance
Shares of NeuroMetrix, Inc. traded low $ -0.03 or -1.89 percent on Wednesday, reaching $ 1.66 with volume of 463.20 thousand shares. The stock opened down for the day at $ 1.68, after closing the previous day trading at $ 1.69.
According to the previous trading day, closing price of $ 1.69, representing a 108.64 % increase from the 52 week low of $ 0.81 and a 94.55 % decrease over the 52 week high of $ 31.00.
The company has a market capital of $ 6.27 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
NeuroMetrix, Inc. will be hosting a conference call at 8:00 AM eastern time on 22nd October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.neurometrix.com
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain.
